Association of chronic stress with plasminogen activator inhibitor-1 in healthy middle-aged men

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 3, 1996, Pages 363-367

  Räikkönen, Katri ^a   Lassila, Riitta ^b   Keltikangas Järvinen, Liisa ^a   Hautanen, Aarno ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b WIHURI RESEARCH INSTITUTE   (Finland)

Author keywords

fibrinolysis; PAI 1; psychosocial; stress; vital exhaustion

Indexed keywords

INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROSCLEROSIS; BODY MASS; DEPRESSION; EXHAUSTION; FATIGUE; FIBRIN DEPOSITION; FIBRINOLYSIS; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; OBESITY; PRIORITY JOURNAL; STRESS; THROMBOSIS;

EID: 0029978066     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.3.363     Document Type: Article

References (39)

1. Ross R. The pathogenesis of atherosclerosis: an update. N Engl J Med. 1986;314:488-500.
2. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes: part I. N Engl J Med. 1992;326:242-250.
3. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes: part II. N Engl J Med. 1992;326:310-318.
4. Juhan-Vague I, Alessi MC. Plasminogen activator inhibitor 1 and atherothrombosis. Thromb Haemost. 1993;70:138-143.
5. Jern C, Eriksson E, Tengborn L, Risberg B, Wadenvik H, Jern S. Changes of plasma coagulation and fibrinolysis in response to mental stress. Thromb Haemost. 1989;62:767-771.
6. Larsson PT, Wiman B, Olsson G, Angelin B, Hjemdal P. Influence of metopropolol treatment on sympatho-adrenal activation of fibrinolysis. Thromb Haemost. 1990;63:482-487.
7. Urano T, Cho M, Takashi S, Sumiyoshi K, Nakamura M, Mori T, Takada Y, Takada A. Changes of parameters in fibrinolytic activity caused by mental stress. Thromb Res. 1990;60:501-507.
8. Hjemdahl P, Chronos NAF, Wilson DJ, Bouloux P, Goodall AH. Epinephrine sensitizes human platelets in vivo and in vitro as studied by fibrinogen binding and P-selectin expression. Arterioscler Thromb. 1994;14:77-84.
9. Larsson PT, Wallen NH, Hjemdahl P. Norepinephrine-induced human platelet activation in vivo is only partly counteracted by aspirin. Circulation. 1994;89:1951-1957.
10. Folts JD, Rowe GG. Epinephrine reverses aspirin inhibition of in vivo platelet thrombus formation in stenosed canine coronary arteries. Thromb Res. 1988;50:507-516.
11. Palmblad J, Blombäck M, Egberg N, Fröberg J, Karlsson C-G, Levi L. Experimentally induced stress in man: effects on blood coagulation and fibrinolysis. J Psychosom Res. 1977;21:87-92.
12. Mattiasson I, Lindgärde F. The effect of psychosocial stress and risk factors for ischemic heart disease on plasma fibrinogen concentration. J Int Med. 1993;234:45-51.
13. Markowe HLJ, Marmot MG, Shipley MJ, Bulpitt CJ, Meade TW, Stirling Y, Vickers MV, Semmence A. Fibrinogen: a possible link between social class and coronary heart disease. BMJ. 1985;291:1312-1314.
14. Rosengren A, Wilhemsen L, Welin L, Tsipogianni A, Teger-Nilsson A, Wedel H. Social influence and cardiovascular risk factors as determinants of plasma fibrinogen concentration in a general population sample of middle-aged men. BMJ. 1990;300:634-638.
15. Appels A. Loss of control, vital exhaustion and coronary heart disease. In: Steptoe A, Appels A, eds. Stress, Personal Control and Health. Brussels, Belgium: John Wiley & Sons Ltd; 1989:215-235.
16. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-Up Program. JAMA. 1979;242:2562-2571.
17. Kluft C, Verheijen JH. Leiden Fibrinolysis Working Party: blood collection and handling procedures for assessment of tissue-type plasminogen activator (tPA) and plasminogen activator inhibitor-1. Fibrinolysis. 1990;4(suppl 2):155-161.
18. Hautanen A, Adlercreutz H. Hyperinsulinemia, dyslipidaemia and exaggerated adrenal androgen response to adrenocorticotropin in male smokers. Diabetologia. 1993;36:1275-1281.
19. Wahlefeld AW. Triglycerides determination after enzymatic hydrolysis. In: Bergmeyer HU, ed. Methods of Enzymatic Analyses. 2nd ed. New York, NY: Verlag Chemie Weinheim/Academic; 1974:1831-1835.
20. Räikkönen K, Keltikangas-Järvinen L, Hautanen A. The role of psychological coronary risk factors in insulin and glucose metabolism. J Psychosom Res. 1994;35:705-713.
21. Cautela JR. Behavior Analysis Forms for Clinical Intervention. Champaign, III: Research Press Co; 1979.
22. Laustiola KE, Lassila R, Kaprio J, Koskenvuo M. Decreased beta-adrenergic receptor density and catecholamine response in male cigarette smokers. Circulation. 1988;78:1234-1240.
23. Appels A, Mulder P. Fatigue and heart disease: the association between vital exhaustion and past, present and future coronary heart disease. J Psychosom Res. 1989;33:727-738.
24. Appels A, Falger PR, Schouten EGW. Vital exhaustion as a risk indicator for myocardial infarction in women. J Psychosom Res. 1993;37:881-890.
25. Van Doornen LJ, Van Blokland RW. The relation of type A behavior and vital exhaustion with physiological reactions to real life stress. J Psychosom Res. 1989;33:715-725.
26. Juhan-Vague I, Alessi MC, Joly P, Thirion W, Vague P, Declerck PJ, Serraminidigi A, Collen D. Plasma plasminogen activator inhibitor in angina pectoris: influence of plasma insulin and acute-phase response. Arteriosclerosis. 1989;9:362-367.
27. Olofsson BO, Dahlen G, Nilsson TK. Evidence of increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. Eur Heart J. 1989;10:77-82.
28. Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985;313:1557-1563.
29. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blombäck M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-9.
30. Vague P, Raccah D, Juhan-Vague I. Hemobiology, vascular disease and diabetes with special reference to impaired fibrinolysis. Metabolism. 1992;41(suppl 1):2-6.
31. Räikkönen K, Hautanen A, Keltikangas-Järvinen L. Association of stress and depression with regional fat distribution in healthy middle-aged men. J Behav Med. 1994;17:605-616.
32. Schneiderman N. Psychophysiologic factors in atherogenesis and coronary artery disease. Circulation. 1987;76(suppl I):I-117-I-123.
33. Rose RM. Psychoendocrinology. In: Wilson JD, Foster DW, eds. Williams Textbook of Endocrinology. Philadelphia, Pa: WB Saunders Co; 1985:653-681.
34. Rizza RA, Mandarion LJ, Gerich JE. Cortisol induced insulin resistance in man: impaired suppression of glucose utilization due to a postreceptor defect of insulin action. J Clin Endocrinol Metab. 1982;54:131-138.
35. Bratusch-Marrain PR, Smith D, DeFronzo RA. The effect of growth hormone on glucose metabolism and insulin secretion in man. J Clin Endocrinol Metab. 1982;55:973-982.
36. Shamoon H, Handler R, Sherwin RS. Synergistic interactions among anti-insulin hormones in the pathogenesis of stress hyper-glycemia in humans. J Clin Endocrinol Metab. 1981;52:1235-1241.
37. Hautanen A, Mänttäri M, Manninen V, Tenkanen L, Huttunen JK, Frick MH, Adlercreutz H. Adrenal androgens and testosterone as coronary risk factors in the Helsinki Heart Study. Atherosclerosis. 1994;105:191-200.
38. Hautanen A, Adlercreutz H. Altered adrenocorticotropin and cortisol secretion in abdominal obesity: implications for the insulin resistance syndrome. J Intern Med. 1993;234:461-469.
39. De Pergola G, De Mitrio V, Cignarelli M, Garruti G, Giorgino F, Meola M, Giorgino R. Inverse relationship between cortisol exertion rate and plasminogen activator inhibitor-1 (PAI-1) antigen and activity in premenopausal obese women. Int J Obes. 1991;15:619-622.